Literature DB >> 18512712

The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road.

Joan M Bathon, Stanley B Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18512712     DOI： 10.1002/art.23723

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  7 in total

1.  Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.

Authors:  Stanley Cohen; Samuel H Zwillich; Vincent Chow; Robert R Labadie; Bethanie Wilkinson
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

Review 2.  [Anti-inflammatory and analgesic electrotherapy. Evidence in rheumatology?].

Authors:  T Müller
Journal:  Z Rheumatol       Date:  2009-09       Impact factor: 1.372

3.  Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.

Authors:  Vibeke Strand; Ronald F van Vollenhoven; Eun Bong Lee; Roy Fleischmann; Samuel H Zwillich; David Gruben; Tamas Koncz; Bethanie Wilkinson; Gene Wallenstein
Journal:  Rheumatology (Oxford)       Date:  2016-02-29       Impact factor: 7.580

4.  Prevalence of Vitamin D Deficiency in Patients Treated for Juvenile Idiopathic Arthritis and Potential Role of Methotrexate: A Preliminary Study.

Authors:  Maciej K Stawicki; Paweł Abramowicz; Adrian Góralczyk; Justyna Młyńczyk; Anna Kondratiuk; Jerzy Konstantynowicz
Journal:  Nutrients       Date:  2022-04-14       Impact factor: 6.706

5.  T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis.

Authors:  Fang Du; Liang-jing Lü; Qiong Fu; Min Dai; Jia-lin Teng; Wei Fan; Shun-le Chen; Ping Ye; Nan Shen; Xin-fang Huang; Jie Qian; Chun-de Bao
Journal:  Arthritis Res Ther       Date:  2008-11-19       Impact factor: 5.156

6.  Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.

Authors:  Vibeke Strand; Joel Kremer; Gene Wallenstein; Keith S Kanik; Carol Connell; David Gruben; Samuel H Zwillich; Roy Fleischmann
Journal:  Arthritis Res Ther       Date:  2015-11-04       Impact factor: 5.156

7.  Deciphering the Potential Pharmaceutical Mechanism of Chinese Traditional Medicine (Gui-Zhi-Shao-Yao-Zhi-Mu) on Rheumatoid Arthritis.

Authors:  Lin Huang; Qi Lv; Duoli Xie; Tieliu Shi; Chengping Wen
Journal:  Sci Rep       Date:  2016-03-03       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.